Ligufalimab, a novel anti-CD47 antibody with no hemagglutination demonstrates both monotherapy and combo antitumor activity

• DOI: 10.1136/jitc-2022-005517
• Publication Date: 2022-11-30T15:15:43Z
• Authors: Tailong Qu; Tingting Zhong; Xinghua Pang; Zhaoliang Huang; Chunshan Jin; Zhongmin Maxwell ...; Baiyong Li; Yu Xia
• Keywords: CD47; Blocking antibody

CD47 is a widely expressed transmembrane glycoprotein that delivers an antiphagocytic signal on macrophages through its interaction with SIRPα. highly in cancer cells and overexpression correlated poor prognosis. blocking antibodies are actively being developed worldwide for therapy, the most challenging concern associated hematotoxicity. Ligufalimab (AK117) novel humanized IgG4 anti-CD47 antibody without hemagglutination effect. Blockade of CD47-SIRPα pathway by AK117 leads to promising therapeutic strategy treatment unique safety features.